Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS pathway mutations are prevalent in many cancers, historically posing challenges for targeted therapy.
• Multi-selective tri-complex RAS(ON) inhibitors represent a novel therapeutic strategy.
• RMC-7977 and RMC-6236 are emerging agents targeting RAS(ON) complexes.

Purpose of the Study:

• To systematically review preclinical and early clinical data for RMC-7977 and RMC-6236.
• To evaluate the efficacy and safety profile of these novel RAS inhibitors.
• To identify potential mechanisms of resistance and future therapeutic combinations.

Main Methods:

• Systematic literature search of Medline, Scopus, ESMO, ASCO, and ClinicalTrials.gov.
• Inclusion of published preclinical studies and early-phase clinical trials.
• Analysis of reported tumor suppression, effects on healthy tissues, and resistance mechanisms.

Main Results:

• RMC-7977 and RMC-6236 demonstrated significant tumor suppression, particularly in non-small cell lung cancer and pancreatic ductal adenocarcinoma.
• Minimal adverse effects were observed in healthy tissues.
• MYC amplification was identified as a primary mechanism contributing to treatment resistance.

Conclusions:

• RMC-7977 and RMC-6236 represent a promising new class of RAS-targeting drugs.
• These inhibitors show efficacy in specific cancer types with a favorable safety profile.
• Further research, including ongoing clinical trials and combination therapies (e.g., with immune-checkpoint blockers), is warranted to overcome resistance and expand therapeutic applications.